Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 2, 1999, Pages 96-109

  Adams, Jerry L ^a   Lee, Dennis ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (4 FLUOROPHENYL) 5 (4 METHYLSULFINYLPHENYL) 3 (4 PYRIDYL)PYRROLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (3 MORPHOLINOPROPYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; 6 AMINO 2 (4 FLUOROPHENYL) 4 METHOXY 3 (4 PYRIDYL) 1H PYRROLO[2,3 B]PYRIDINE; 7 HYDROXYSTAUROSPORINE; BALANOL; COMPLEMENTARY RNA; FLAVOPIRIDOL; L 779450; L 786134; MIDOSTAURIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE; RO 09 2210; ROSCOVITINE; RUBOXISTAURIN; STAUROSPORINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CATALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; IMMUNE RESPONSE; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0032945648     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (108)

1. Schlessinger J, Ullrich A: Growth factor signalling by receptor tyrosine kinases. Neuron (1992) 9:383-391.
2. Hanks SK, Hunter T: Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J(1995) 9:576-596.
3. Burke TR Jr, Yao ZJ, Smyth MS, Ye B: Pnosphotyrosylbased motifs in the structure-based design of proteintyrosine kinase-dependent signal transduction inhibitors. CurrPharm Des (1997) 3:291-304.
4. McMahon G, Sun L, Liang C, Tang C: Protein kinase inhibitors: structural determinants for target specificity. CurrOpin Drug Discov Dev (1998) 1(2):131-146.
5. Lawrence DS, Niu J: Protein kinase inhibitors: the tyrosinespecific protein kinases. Pharmacol Ther(1938) 77:81-114.
6. Bridges AJ: Current progress towards the development of tyrosine kinase inhibitors as anticancer agents. Emerging Drugs (1998) 3:279-292.
7. Lee JC, Badger AM, Griswold DE, Dunnington D, Truneh A, Votta B, White JR, Young PR, Bender PE: Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann New York Acad Sci (1993) 696:149-170.
8. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature(1994) 372:739-746.
9. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC: SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett (1995) 364:229-233.
10. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR: Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophy Res Comm (1997) 235:533-553.
11. Goedert M, Cuenda A, Craxton M, Jakes R, Cohen P: Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6)-comparison of its substrate specificity with that of other SAP kinases. EMBO J(1997) 16:3563-3571.
12. Cohen P: The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol (1997)7:353-361.
13. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL, Lee JC: Pyridinyl imidazole inhibitors of p38 MAP kinase bind in the ATP site. JBiolChem (1997) 272:12116-12121.
14. Lisnock JM, Tebben A, Frantz B, O'Neill EA, Croft G, O'Keffe SJ, Li B, Hacker C, de Laszlo S, Smith A, Ubby B, Liverton N, Hermes J, LoGrasso P: Molecular basis for p38 kinase inhibitor specificity. /oc/7em/s//y(1998) 37:16573-16581.
15. Gallagher TF, Seibel GL, Kassis S, Laydon JT, Lee JC, Lee D, Boehm JC, Bender PE, Erhard KF, Krog AJ, Hofmann GA, Adams JL: Regulation of stress-induced cytokine production by pyridinylimidazoles: inhibition of CSBP kinase. Bioorg Med Chem (1997) 5:49-64.
16. Hanson GJ: Inhibitors of p38 kinase. Exp Opin Ther Patents (1997)7(7):729-733.
17. de Laszlo SE, Visco D, Agarwal L, Chang L, Chin J, Croft G, Forsyth A, Fletcher D, Frantz B, Hacker C, Hanlon W, Harper C, Kostura M, Li B, Luell S, MacCoss M, Mantlo N, O'Neill EA, Orevillo C, Pang M, Parsons J, Rolando A, Sahly Y, Sidler K, Widmer WR, O'Keefe SJ: Pyrroles and other heterocycles as inhibitor of p38 kinase. Bioorg Med Chem Lett (1998) 8:2689-2694.
18. Henry JR, Rupert KG, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Schafer PH, Siekeirka, JJ: Potent inhibitors of MAP kinase p38. Bioorg Med Chem Lett (1998) 8:3335-3340.
19. Henry JR, Rupert KG, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Fahmy B, Olini GC, Davis JE, PellegrinoGensey JL, Schafer PH, Siekeirka JJ: 6-Amino-2-(4-fluorophenyl)-4- methoxy-3- (4-pyridyl)- 7H-pyrrolo[2,3-b] pyridine (RWJ 68354): A potent and selective p38 kinase inhibitor. J Med Chem (1998) 41:4196-4198.
20. Adams JL, Boehm JC, Kassis S, Gorycki PD, Webb EF, Hall R, Sorenson M, Lee JC, Ayrton A, Griswold DE, Gallagher TF: Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg Med Chem Lett (1998) 8:3111 -3116.
21. Wang ZL, Canagarajah BJ, Boehm JC, Kassis S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ Structural basis of inhibitor selectivity in MAP kinases. Structure (1998) 6:1117-1128.
22. Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD: Pharmacological effects of SB 220025, a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharm Exp 777er(1998) 284: 687-692.
23. Vertex Press Release, News Wire 8 July, 1998.
24. Walker DH: Small molecule inhibitors of cyclin-dependent kinases: Molecular tools and potential therapeutics. Curr Topics in Microbiol Immunol (1998) 227:149-165.
25. Coleman KG, Lyssikatos JP, Yang BV: Chemical inhibitors of cyclin-dependent kinases. Ann Rep Med Chem (1997) 32:171-179.
26. Meijer L, Kim SH: Chemical inhibitors of cyclin-dependent kinases. Meth Enzym (1997) 283:113-129.
27. Vesely J, Havlicek L, Stmad M, Blow JJ, Donella-Deana A, Pinna L, Letnam DS, Kato JY, Detivaud L, Leclerc S, Meijer L: Inhibition of cyclin-dependent kinases by purine analogues. EurJBiochem (1994) 224:771-786.
28. Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Stmad M: Cytokinin-derived cyclin-dependent kinases inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem (1997) 40:408-412.
29. Meijer L, Borgne A, Mulner O, Chong JPJ, Blow JJ, Inagaki N, Inagaki M, Delcros J-G, Moulinoux JP: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. EurJBiochem (1997) 243:527-536.
30. Kim SH, Schulze-Hahmen U, Brandsen J, de Azevedo WF Jr Structural basis for chemical inhibition of CDK2. Prog Cell Cycle Res (1996) 2:137-145.
31. Kim SH: Structure-based inhibitor design for CDK2, a cell cycle controlling protein kinase. Pure Appl Chem (1998) 70:555-565.
32. Norman TC, Gray NS, Koh JT, Schultz PG: A structure-based library approach to kinase inhibitors. J Am Chem Soc (1996)118:7430-7431.
33. Gray NS, Wodicka L, Thunnissen AMWH, Norman TC, Kwon S, Espinoza FH, Morgan DO, Bames G, Leclerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (1998) 281:533-538.
34. Schow SR, Mackman RL, Blum CL, Brooks E, Harsma AG, Joly A, Kerwar SS, Lee G, Shiftman D, Nelson MG, Wang X, Wick MM, Zhang X, Lum RT: Synthesis and activity of 2,6,9-trisubstituted purines. Bioorg Med Chem Lett (1997) 7:2697-2702.
35. Nugiel DA, Cornelius LAM, Corbett JW: Facile preparation of 2,6-disubstituted purines using solid-phase chemistry. J Org Chem (1997) 62:201-203.
36. Fiorini MT, Abell C: Solution-phase synthesis of 2,6,9-trisubstituted purines. Tet Lett (1998) 39:1827-1830.
37. Imbacn P, Capraro HG, Füret P, Mett H, Meyer T, Zimmermann J: 2,6,9-Trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett (1999) 9:91-96.
38. Sasaki S, Hashimoto T, Obana N, Yasuda H, Uehara Y, Maeda M: Design of new inhibitors for CDC2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett (1998) 8:1019-1022.
39. Cohen BA, Colas P, Brent R: An artificial cell-cycle inhibitor isolated from a combinatorial library. P roc Natl Acad Sci USA (1998) 95:14272-14277.
40. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sousville, EA: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 16:2986-2999.
41. Sedlacek HH, Czech J, Naik, R, Kaur G, Woriand P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E: Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy, Int J Oncol (1996) 9:1143-1168.
42. Harris W, Wilkinson SE, Nixon JS: Recent developments in protein kinase C inhibitors. Exp Opin Ther Patents (1997) 7:63-68.
43. Hu H: Recent discovery and development of selective protein kinase C inhibitors. Drug Discovery Today (1996) 1:438:447.
44. Goschcr A: Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol (1998) 31:721-728.
45. Kulanthaivel P, Hallock YF, Boras C, Hamilton SM, Janzen WP, Ballas LM, Loomis CR, Jiang JB: Balanol: a novel and potent inhibitor of protein kinase C from the fungus verticillium balanoides. J Am Chem Soc (1993) 115:6452-6453.
46. Koide K, Bunnage ME, Paloma LG, Kanter JR, Taylor SS, Brunlon LL, Nicolaou KC: Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol. Chem Biol (1995) 2:601-608.
47. Defauw JM, Murphy MM, Jagdmann GE Jr, Hu H, Lampe JW, Hollinshead SP, Mitchell TJ, Crane HM, Heerding JM, Mendoza JS, Davis JE, Darges JW, Hubbard FR, Hall SE: Synthesis and protein kinase C inhibitory activities ol acyclic balanol analogs that are highly selective foi protein kinase C over protein kinase A. J Med Chem (1996] 39:5215-5227.
48. Lai YS, Menaldino DS, Nichols JB, Jagdmann GE Jr, Mylott F, Gillespie J, Hall SE: Ring size effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. Bioorc MedChemLett (1995) 5:2151-2154.
49. Mendoza JS, Jagdmann GE, Gosnell PA: Synthesis and biological evaluation of conformationally constrained bicyclic and tricyclic balanol analogues as inhibitors ol protein kinase C. Bioorg Med Chem Lett (1995) 5:2211-2216.
50. Hu H, Hollinshead SP, Hall SE, Kalter K, Ballas LM: Synthesis and protein kinase C inhibitory activities of indane analogs of balanol. Bioorg Med Chem Lett (1996) 6:973-978.
51. Lai YS, Mendoza JS, Jagdmann GE Jr, Menaldino DS, Biggers CK, Heerding JM, Wilson JW, Hall SE, Jiang JB, Janzen WP, Ballas LM: Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety. J Med Chem (1997) 40:226-235.
52. Crane CM, Menaldino DS, Jagdmann GE Jr, Darges JW, Buben JA: Increasing the cellular PKC inhibitory activity ol balanol: A study of ester analogs. Bioorg Med Chem Let (1995)5:2133-2138.
53. Heerding JM, Lampe JW, Darges JW, Stamper ML: Protein kinase C inhibitory activities of balanol analogs bearing carboxylic acid replacements. Bioorg Med Chem Let (1995)5:1839-1842.
54. Sodeoka M, Adachi MAA, Uotsu K, Shibasaki M: Rational design, synthesis, and evaluation of a new type of PKC inhibitor. JAm Chem Soc (1998) 120:457-458.
55. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald III JH, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM: (SJ-13[(Dimethylamino)methyl]-10, 11, 14, 15-tetrahydro-4,9:16,21dimetheno-1 H,13/Mibenzo[e,Ar]pyrrolo[3,4-/r][1,4,13]oxadiaza cyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C. J Med Chem (1996) 39:2664-2671.
56. Inoguchi T, Battan R, Handler E, Sportsman JR; Heath W, King GL: Preferential elevation of protein kinase C isoform t and diacylglycero! levels in the aorta and heart of diabetic rats: differential reversibility to glycémie control by islet cell transplantation. Proc Natl Acad Sci USA (1992) 89:11059-11063.
57. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kem TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science (1996] 272:728-731.
58. Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibition ol intraocular neovascularization caused by retinal ischemia in pigs by PKCB inhibition with LY333531. Inves Ophthalmol Vis Sci (1998) 39:171-179.
59. National Cancer Institute. CancerNet. httptfcancemet.nci.nih.govl. Current information on scope and status of UCN-01 clinical trials can be found on the NCI web site.
60. Mehta AB, Virchis AE, Jones DT, Hart SM, Wickremasinghe RG, Prentice HG, Yong KL, Csermak-Renner AMK, Ganeshaguru K: Preliminary results of a phase 2 study on a protein kinase C inhibitor (CGP 41251) in low grade lymphoproliferative disorders. /oo/(1997) 90(Part 2, Supp! 1):3646.
61. Gescher A: Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol (1998) 31:721-728.
62. Alessi OR: The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1b (Rsk-2) and p70S6 kinase. FEBS Lett (1997) 402:121-123.
63. Beltman J, McCormick F, Cook SJ: The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-jun expression, and activates jun N-terminal kinase. J Biol Chem (1997) 271:27018-27024.
64. Favata MF, Horiuchi KY, Manos, EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherte PA, Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Cr;em(1998) 273:18623-18632.
65. Duncia JV, Santella III JB, Higley A, Pitts WJ, Wityak J, Frietze WE, Rankin FW, Sun JH, Earl RA, Tabaka AC, Teleha CA, Blom KF, Favata MF, Manos EJ, Daulerio AJ, Stradley DA, Horiuchi K, Copeland RA, Scherte PA, Trzaskos JM, Magolda RL, Trainor GL, Wexler RR, Hobbs FW, Oison RE: MEK Inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett (1998) 8:2839-2844.
66. Williams DH, Wilkinson SE, Purton T, Lamont A, Flotow H, Murray EJ: Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity. B/oc/?em/s//y(1998) 37:9579-9585.
67. Identification of potent, selective inhibitors of raf protein kinase. American Association for Cancer Research, New Orleans, USA, April 1998: Poster 3793.
68. Crooke ST (Ed): Antisense research and application. In: Handbook Experimental Pharm (1998) 131.
69. Henry SP, Monteith D, Bennett F, Levin AA: Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-ot and C-raf kinase. Anticancer Drug Des (1997) 12:409-420.
70. Crooke ST (Ed): Antisense research and application. In: Handbook Exp Pharm (1998) 131:463-476.
71. McGraw K, McKay R, Miraglia L, Boggs RT, Pribble JP, Muller M, Geiger T, Fabbro D, Dean NM: Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics. Anticancer Drug Des (1997) 12:315-326.
72. Tong L, Pav S, White DH, Rogers S, Crane KM, Cywin CL, Brown ML, Pargellis CA: A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct Biol (1997) 4:311 -316.
73. Wilson KP, McCaff PG, Hsiao K, Pazhanisamy S, Galullo V, Bemis GW, Fitzgibbon MJ, Caron PR, Murcko HA, Su MSS: The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol (1997)4:423-431.
74. Hanks S, Quinn AM: Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members. Methods Enzymol (1991 ) 200:38-62.
75. Gum R, McLaughlin MM, Kumar S, Wang ZL, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, Young PR: Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem (1998) 273:15605-15610.
76. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M: Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem B/o/t 1998) 5:321-328.
77. Fox T, Coll JT, Xie X, Ford PJ, Germann UA, Porter MD, Parhanisamy S, Fleming MA, Galullo V, Su MSS, Wilson KP: A single amino acid makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci (1998) 7:2249-2255.
78. Shah K, Liu Y, Deirmengian C, Shokat KM: Engineering unnatural nucleotide specificity for rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci USA (1997) 97:3565-3570.
79. Bishop AC, Shah K, Liu Y, Witucki L, Kung C, Shokat KM: Design of allele-specific inhibitors to probe protein kinase signalling. Curr/o/(1998) 8:257-266.
80. Trumpp-Kallmeyer S, Rubin JR, Humblet C, Hamby JM, Showalter HDH: Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J Wed Chem (1998) 41:1752-1763.
81. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, Eliseenkova AV, Green D, Schlessinger J, Hubbard SR: Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J (1998) 17:5896-5904.
82. MERCK & Co INC (Selnick HG. Claremon DA, Liverton NJ): Substituted imidazoles having anticancer and cytokine inhibitory activity. WO-09712876 (1997).
83. MERCK & Co INC (de Laszlo SE, Mantlo NB, Ponticello GS, Selnick HG, Liverton NJ): 2-Substituted 3,5-diarylpyrroles that inhibit cytokine production. WO-09705877 (1997).
84. MERCK & Co INC (de Laszlo SE, Mantlo NB, Ponticello GS, Selnick HG, Liverton NJ): 2,3,5-Triarylpyrroles that inhibit cytokine production. WO-09705878 (1997).
85. MERCK & Co INC (de Laszlo SE, Mantlo NB): 2-Substituted arylpyrroles for the treatment of inflammatory disorders. WO-09716426 (1997).
86. MERCK & Co INC (de Laszlo SE, Mantlo NB de Laszlo SE, Mantlo NB): 2,5-Substituted aryl pyrroles for the treatment of inflammatory disorders. WO-09716441 (1997).
87. SEARLE & Co (Anantanarayan A, Clare M, Collins PW, Crich JZ, Devraj R, Flynn DL, Geng L, Hanson GJ, Koszyk FJ, Liao S, Partis R, Selness SR, South MS, Stealey MA, Weier RM, Xu X): Substituted pyrazoles as p38 kinase inhibitors. WO09852940(1998).
88. SEARLE & Co (Hanson GJ, Liao S): Pyrazole derivatives as p38 kinase inhibitors. WO-09852941 (1998).
89. SEARLE & Co (Anantanarayan A, Clare M, Geng L, Hanson G, Partis RA, Stealey MA, Weier RM): 3(5)-Heteroarylsubstituted pyrazoles as p38 kinase inhibitors. WO09852937(1998).
90. SMITHKLINE BEECHAM CORP (Adams JL, Gallagher T, Osifo IK): Novel pyrazole and pyrazoline substituted compounds and their use as p38 kinase inhibitors. WO-09856377 (1998).
91. SMITHKLINE BEECHAM CORP (Gallagher TF, Thompson SM): Novel 4,5-bisarylpyrimidine derivatives useful as inhibitors of cytokine production. WO-09733883 (1997).
92. AMGEN INC (Spohr UD, Malone MJ, Mantlo NB, Zablocki JA): Methods and compositions for the treatment of inflammation and pain. WO-09824780 (1998).
93. AMGEN INC (Spohr UD, Malone MJ, Mantlo NB): Methods and compositions for the treatment of inflammation and pain. WO-09824782 (1998).
94. AMGEN INC (Zablocki JA, Tarlton E, Rizzi JP, Mantlo NB): Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents. WO-09822457 (1998).
95. OflTHO-McNEiL INC (Dodd JH, Henry JR, Rupert K): Substituted pyrrolopyridines useful in the treatment of inflammatory diseases. WO-09847899 (1998).
96. SMITHKLINE BEECHAM CORP (Adams JL, Garigipati RS, Sorenson ME): Novel cycloalkyl substituted imidazoles for the treatment of inflammation, rheumatoid arthritis, osteoarthritis, sepsis and viral infection. WO-09725048 (1997).
97. MERCK & Co INC (Liverton NJ, Butcher JW, Claremon DA, Bilodeau MT): Novel substituted imidazoles are cytokine inhibitors useful in the treatment of cytokine-mediated diseases. WO-09747618 (1997).
98. VERTEX PHARMACEüTICALS INC (Bemis GW, Salituro FG, Duffy JP, Cochran JE, Harrington EM, Murcko MA, Wilson KP, Su M, Galullo VP): Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase. WO-09827098 (1998).
99. SMITHKLINE BEECHAM CORP (Boehm JC, Chan GW): Novel piperidine containing compounds. WO-09828292 (1998).
100. BAYER CORP (Ranges G, Scott W, Bombara M, Rauner D, Redman A, Smith R, Paulsen H, Chen J, Gunn D, Renick J): Inhibition of p38 kinase activity using substituted arylureas. WO-09852558 (1998).
101. NOVARTIS AG (Zimmermann J, Capraro HG, Peterli P, Furet P): Purine derivatives are CDC2 cyclin kinase inhibitors. WO09716452(1997).
102. HOECHST MARION ROUSSEL INC (Jones WD, Ciske FL, Dinerstein RJ, Diekema KA): Alkyloxyamino substituted fluorenones and their use as protein kinase C inhibitors. WO-09745397(1997).
103. MERCK & Co INC (Bills GF, Diez MT, Dombrawski AW, Falconi ND, Goetz MA, Heimbrook DC, Hensens ÖD, Huang L, Huber HE): MEK inhibiting lactones. GB-02323845 (1998).
104. MERCK & Co INC (Claremon DA, Heimbrook DC, Liverton N, Seinick HG, Huber HE, Manllo NB, Patrick DR): Methods of treating RAF mediated disease. GB-02306108 (1997).
105. SUGEN INC (Tang PC, McMahon G, Weinberger H, Kutscher B, App H): Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds. WO09850370 (1998).
106. BAYER CORP (Wood JE, Wild H, Rodgers DH, Lyons J, Katz ME, Caringal YV, Dally R, Lee W, Smith RA, Blum CL): Substituted urea derivatives which inhibit raf kinase useful as anticancer agents. WO-09852559 (1998).
107. ZENECA LTD (Hedge PJ, Boyle FT): Novel substituted benzamide compounds as raf kinase inhibitors. WO09822103(1998).
108. CELLTECH THERAPEUTICS LTD (Davis PD, Moffat DFC, Davis JM, Hutchings MC): Novel anilinopyrimidine derivatives are protein kinase inhibitors for treating autoimmune and hyperproliferation disorders. WO-09719065 (1997).